SEC Comment Letter 0000000000-25-003255 to Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc.
Date: March 26, 2025 · CIK: 0001826457 · Accession: 0000000000-25-003255
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-285942
Letter
Re: Monte Rosa Therapeutics, Inc. Registration Statement on Form S-3 Filed March 20, 2025 File No. 333-285942 Dear Markus Warmuth M.D.:
March 26, 2025
Markus Warmuth, M.D. Chief Executive Officer Monte Rosa Therapeutics, Inc. 321 Harrison Avenue, Suite 900 Boston, MA 02118
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Kristen McCarthy, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 26, 2025 Markus Warmuth, M.D. Chief Executive Officer Monte Rosa Therapeutics, Inc. 321 Harrison Avenue, Suite 900 Boston, MA 02118 Re: Monte Rosa Therapeutics, Inc. Registration Statement on Form S-3 Filed March 20, 2025 File No. 333-285942 Dear Markus Warmuth M.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Kristen McCarthy, Esq. </TEXT> </DOCUMENT>